Qurient

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

Notice

2024-12-10	큐리언트, 美 학회에서 MD앤더슨과의 혈액암 임상 계획 발표
2024-12-05	큐리언트 아드릭세티닙(Q702), 만성 이식편대숙주질환(cGvHD) 치료제로 출사표
2024-11-19	큐리언트, 동구바이오제약에 60억 규모 영구CB 발행 결정…"밸류업 확신"
2024-10-25	큐리언트, MD앤더슨과 아드릭세티닙 병용임상 개시
2024-09-27	큐리언트 임시주주총회 성료…동구바이오제약과 협력 강화로 새로운 도약 기대

Company

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More
Business philosophy

Innovation for unmet medical needs

Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More
Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More
IR/PR

Dear Qurient shareholders

Qurient would like to share brief updates on current progress made on its portfolio programs. See More